MXPA04007427A - Formulaciones de azitromicina granuladas por via seca. - Google Patents
Formulaciones de azitromicina granuladas por via seca.Info
- Publication number
- MXPA04007427A MXPA04007427A MXPA04007427A MXPA04007427A MXPA04007427A MX PA04007427 A MXPA04007427 A MX PA04007427A MX PA04007427 A MXPA04007427 A MX PA04007427A MX PA04007427 A MXPA04007427 A MX PA04007427A MX PA04007427 A MXPA04007427 A MX PA04007427A
- Authority
- MX
- Mexico
- Prior art keywords
- azithromycin
- mga
- dihydrate
- pharmaceutical formulation
- dry granulated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Abstract
Esta invencion se relaciona con una formulacion farmaceutica, en forma de comprimidos, sobrecillo o polvo para formar una forma de dosificacion en suspension, que comprende particulas granuladas por via seca de una forma no dihidrato de la azitromicina y, opcionalmente, uno o mas excipientes farmaceuticamente aceptables; preferiblemente, la formulacion farmaceutica es un comprimido que contiene entre aproximadamente 40% en peso y aproximadamente 85% en peso de azitromicina no dihidrato; mas preferiblemente, la formulacion farmaceutica contiene azitromicina no dihidrato seleccionada de las formas B, D, E, F, G, H, J, M, N, O, P, Q, R, o de sus mezclas; incluso mas preferiblemente, la invencion se refiere a una formulacion farmaceutica en la que la dosificacion de azitromicina es 250 mgA, 500 mgA, 600 mgA o 1000 mgA; la presente invencion se refiere ademas a una particula de azitromicina granulada por via seca, que comprende una forma de azitromicina, seleccionada de las formas D, E, F, G, H, J, M, N, P, Q, R, y mezclas de formas no dihidrato, y al menos un excipiente farmaceuticamente aceptable.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35404102P | 2002-02-01 | 2002-02-01 | |
| PCT/IB2003/000212 WO2003063838A1 (en) | 2002-02-01 | 2003-01-20 | Dry granulated formulations of azithromycin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04007427A true MXPA04007427A (es) | 2004-10-11 |
Family
ID=27663280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04007427A MXPA04007427A (es) | 2002-02-01 | 2003-01-20 | Formulaciones de azitromicina granuladas por via seca. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7438924B2 (es) |
| EP (1) | EP1478347A1 (es) |
| JP (1) | JP2005526020A (es) |
| KR (1) | KR100676025B1 (es) |
| CN (1) | CN1646104A (es) |
| AR (1) | AR038371A1 (es) |
| AU (1) | AU2003201146B2 (es) |
| BR (1) | BR0307331A (es) |
| CA (1) | CA2474809A1 (es) |
| CO (1) | CO5611118A2 (es) |
| MX (1) | MXPA04007427A (es) |
| NO (1) | NO20043644L (es) |
| NZ (1) | NZ534234A (es) |
| PL (1) | PL372394A1 (es) |
| RU (1) | RU2283092C2 (es) |
| TW (1) | TW200306865A (es) |
| WO (1) | WO2003063838A1 (es) |
| ZA (1) | ZA200405805B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20020231A2 (en) | 2002-03-18 | 2003-12-31 | Pliva D D | ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A |
| BR0215193A (pt) * | 2001-12-21 | 2004-11-16 | Pfizer Prod Inc | Formulações de azitromicina diretamente compressìveis |
| HRP20020614A2 (en) | 2002-07-22 | 2004-06-30 | PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. | Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a |
| EP2422772A3 (en) * | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
| JP3444874B1 (ja) * | 2002-12-02 | 2003-09-08 | 高砂香料工業株式会社 | 顆粒状香料およびその製造方法 |
| US20070185194A1 (en) * | 2003-07-01 | 2007-08-09 | Kamal Mehta | Stable oral compositions of azithromycin monohydrate |
| WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
| WO2005053651A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate compositions with improved stability |
| US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
| WO2005053655A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Method for making pharmaceutical multiparticulates |
| UA78793C2 (en) * | 2003-12-04 | 2007-04-25 | Pfizer Prod Inc | Oral dosage form of azitromycin with decreased side effects |
| US7468428B2 (en) | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| US20080199527A1 (en) * | 2004-12-21 | 2008-08-21 | Pfizer Inc. | Enteric Coated Azithromycin Multiparticulates |
| EA013161B1 (ru) * | 2005-06-08 | 2010-02-26 | Орион Корпорейшн | Дозированная форма для перорального применения |
| JP5508003B2 (ja) | 2006-06-30 | 2014-05-28 | アイスイティカ ピーティーワイ リミテッド | ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法 |
| US8808751B2 (en) * | 2006-06-30 | 2014-08-19 | Iceutica Pty Ltd. | Methods for the preparation of biologically active compounds in nanoparticulate form |
| EP2086512A2 (en) * | 2006-10-27 | 2009-08-12 | Janssen Pharmaceutica N.V. | Dry granulated pharmaceutical compositions and methods for producing same |
| US8951562B2 (en) | 2006-11-10 | 2015-02-10 | Atacama Labs Oy | Method and apparatus or dry granulation |
| FI20070521L (fi) * | 2006-11-10 | 2008-05-11 | Atacama Labs Oy | Rakeita, tabletteja ja rakeistusmenetelmä |
| US8568779B2 (en) | 2007-01-11 | 2013-10-29 | Kaneka Corporation | Method for producing coenzyme Q10 particle |
| WO2009135946A1 (en) * | 2008-05-09 | 2009-11-12 | Atacama Labs Oy | Method and apparatus for dry granulation |
| US8106111B2 (en) | 2009-05-15 | 2012-01-31 | Eastman Chemical Company | Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions |
| RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
| JP5585920B2 (ja) * | 2010-12-27 | 2014-09-10 | 富田製薬株式会社 | 粒子状製剤 |
| CN106117344B (zh) | 2011-04-12 | 2020-11-03 | 诺沃—诺迪斯克有限公司 | 双酰化glp-1衍生物 |
| WO2013088274A1 (en) | 2011-12-14 | 2013-06-20 | Wockhardt Limited | Anhydrous amorphous azithromycin composition free of azithromycin dihydrate |
| HRP20231613T1 (hr) | 2012-03-22 | 2024-03-15 | Novo Nordisk A/S | Pripravci koji sadrže sredstvo za unošenje i njihova priprava |
| ES2715308T3 (es) | 2012-03-22 | 2019-06-03 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y su preparación |
| US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
| EP2863895B1 (en) | 2012-06-20 | 2021-04-14 | Novo Nordisk A/S | Tablet formulation comprising a peptide and a delivery agent |
| EP3746111B1 (en) | 2018-02-02 | 2023-07-19 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| WO1989000576A1 (en) * | 1987-07-09 | 1989-01-26 | Pfizer Inc. | Azithromycin dihydrate |
| WO1989002271A1 (en) * | 1987-09-10 | 1989-03-23 | Pfizer | Azithromycin and derivatives as antiprotozoal agents |
| TW271400B (es) * | 1992-07-30 | 1996-03-01 | Pfizer | |
| US5795871A (en) | 1994-04-26 | 1998-08-18 | Nobuhiro Narita | Pharmaceutical composition for treatment of non-small cell lung cancer |
| US5605889A (en) * | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| UA41995C2 (uk) * | 1994-05-06 | 2001-10-15 | Пфайзер Інк. | Лікарська форма азитроміцину з контрольованим вивільненням ( варіанти ), спосіб її введення, спосіб її виготовлення і спосіб лікування інфекційних захворювань ссавців з її використанням ( варіанти ) |
| US6339063B1 (en) * | 1997-09-10 | 2002-01-15 | Merck & Co., Inc. | 9a-azalides as veterinary antimicrobial agents |
| JP2001515865A (ja) | 1997-09-10 | 2001-09-25 | メルク エンド カムパニー インコーポレーテッド | 家畜抗菌剤としての９ａ−アザライド |
| CA2245398C (en) * | 1998-08-21 | 2002-01-29 | Apotex Inc. | Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof |
| ES2229804T3 (es) * | 1998-11-30 | 2005-04-16 | Teva Pharmaceutical Industries Ltd. | Etannolato de azitromicina, procedimiento para su fabricacion y composiciones farmaceuticas que lo contienen. |
| FR2793690B1 (fr) * | 1999-03-30 | 2003-01-03 | Cll Pharma | Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique |
| AU2001214115A1 (en) | 2000-08-01 | 2002-02-13 | Habil F. Khorakiwala | Process for the preparation of anhydrous azithromycin |
| HUP0400446A2 (hu) | 2001-05-22 | 2004-09-28 | Pfizer Products Inc. | Azitromicin kristályformái |
| HUP0402291A2 (hu) * | 2001-10-18 | 2005-03-29 | Teva Pharmaceutical Industries Ltd. | Stabilizált azithromycin összetételek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
-
2003
- 2003-01-20 WO PCT/IB2003/000212 patent/WO2003063838A1/en active Application Filing
- 2003-01-20 KR KR1020047011565A patent/KR100676025B1/ko not_active IP Right Cessation
- 2003-01-20 NZ NZ534234A patent/NZ534234A/en unknown
- 2003-01-20 PL PL03372394A patent/PL372394A1/xx not_active Application Discontinuation
- 2003-01-20 JP JP2003563532A patent/JP2005526020A/ja active Pending
- 2003-01-20 MX MXPA04007427A patent/MXPA04007427A/es active IP Right Grant
- 2003-01-20 RU RU2004123624/15A patent/RU2283092C2/ru not_active IP Right Cessation
- 2003-01-20 AU AU2003201146A patent/AU2003201146B2/en not_active Ceased
- 2003-01-20 CA CA002474809A patent/CA2474809A1/en not_active Abandoned
- 2003-01-20 CN CNA038075105A patent/CN1646104A/zh active Pending
- 2003-01-20 BR BR0307331-9A patent/BR0307331A/pt not_active IP Right Cessation
- 2003-01-20 EP EP03734611A patent/EP1478347A1/en not_active Withdrawn
- 2003-01-28 TW TW092101816A patent/TW200306865A/zh unknown
- 2003-01-30 AR ARP030100270A patent/AR038371A1/es unknown
- 2003-01-31 US US10/355,575 patent/US7438924B2/en not_active Expired - Fee Related
-
2004
- 2004-07-21 ZA ZA200405805A patent/ZA200405805B/en unknown
- 2004-07-22 CO CO04070289A patent/CO5611118A2/es not_active Application Discontinuation
- 2004-08-31 NO NO20043644A patent/NO20043644L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200405805B (en) | 2006-05-31 |
| PL372394A1 (en) | 2005-07-25 |
| JP2005526020A (ja) | 2005-09-02 |
| CO5611118A2 (es) | 2006-02-28 |
| US20030228357A1 (en) | 2003-12-11 |
| BR0307331A (pt) | 2004-12-07 |
| KR100676025B1 (ko) | 2007-01-29 |
| AR038371A1 (es) | 2005-01-12 |
| RU2004123624A (ru) | 2005-04-10 |
| RU2283092C2 (ru) | 2006-09-10 |
| NZ534234A (en) | 2007-05-31 |
| NO20043644L (no) | 2004-09-21 |
| US7438924B2 (en) | 2008-10-21 |
| CA2474809A1 (en) | 2003-08-07 |
| AU2003201146B2 (en) | 2008-04-17 |
| WO2003063838A1 (en) | 2003-08-07 |
| TW200306865A (en) | 2003-12-01 |
| KR20040079954A (ko) | 2004-09-16 |
| CN1646104A (zh) | 2005-07-27 |
| EP1478347A1 (en) | 2004-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04007427A (es) | Formulaciones de azitromicina granuladas por via seca. | |
| MXPA04003027A (es) | Metodos para granulacion humeda de azitromicina. | |
| AU2001236207A1 (en) | Powder formulation | |
| JP2005524658A5 (es) | ||
| AU6294501A (en) | Spray drying process and compositions of fenofibrate | |
| CA2339991A1 (en) | Microemulsions as solid dosage forms for oral administration | |
| RS20050239A (en) | Solid pharmaceutical formulations comprising telmisartan | |
| HUP9801615A2 (hu) | Szimetikon/vízmentes kalcium-foszfát-kompozíciók | |
| HUP1300117A2 (en) | Pharmaceutical formulations for dry powder inhalers in the form of hard pellets | |
| CA2389349A1 (en) | Aerosol composition comprising formoterol | |
| HUP0303398A3 (en) | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof and pharmaceutical compositions containing the same | |
| HUP0402026A3 (en) | 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them | |
| GB0107106D0 (en) | Powder inhaler formulations | |
| WO2006123357A3 (en) | Oral controlled release composition containing levetiracetam | |
| MXPA04005105A (es) | Formulaciones de acitromicina directamente compresibles. | |
| HUP0202781A2 (hu) | Béta-karbolin szemcsés formája, ezt tartalmazó gyógyszerkészítmények, előállításaik és alkalmazásuk | |
| AP1776A (en) | Reconstitutable parenteral composition containing a cox-2 inhibitor. | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| HUP0401747A3 (en) | Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds | |
| HUP0301390A2 (hu) | Valzartánt tartalmazó orális gyógyászati készítmény | |
| MY137846A (en) | Processes for the preparation of oral dosage formulations of modafinil | |
| HUP0500097A2 (hu) | Nyújtott/szabályozott hatóanyag-leadású szilárd készítmény, mint kisebb dózisveszteséget mutató új hatóanyag-adagoló rendszer | |
| CA2435714A1 (en) | Fenofibrate tablets | |
| HUP0303450A2 (hu) | Eljárás metoprololt tartalmazó mikrorészecskék előállítására és ezeket tartalmazó gyógyszerkészítmények | |
| WO2005123086A3 (en) | Ziprasidone dosage form |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |